Eli Lilly CEO points to retatrutide as next wave after Mounjaro and Zepbound propel quarterly jump

Eli Lilly’s second-quarter results showed what the company’s weight-loss medicines are already doing for sales, and CEO David Ricks used the update to argue that the next chapter could come from retatrutide.

According to the report, Lilly’s revenue rose 48% in the quarter, and the company’s performance exceeded Wall Street expectations. The upside was attributed primarily to continued demand for Mounjaro and Zepbound, Lilly’s two widely used drugs for weight management and metabolic disease.

Mounjaro and Zepbound are part of Lilly’s rapidly expanding portfolio in the obesity and related-care space. In the marketplace, demand has been a central driver of revenue momentum for manufacturers developing incretin-based therapies, where patients, payers, and healthcare systems are trying to manage both chronic conditions and long-term costs.

Beyond the current franchise, Ricks indicated confidence in retatrutide, an investigational weight-loss medicine. In the post, he positioned retatrutide as a potential growth engine after the company’s established products have already scaled.

The CEO’s comments framed Lilly’s outlook in unusually emphatic terms, stating the company’s future had “never been brighter.” The message suggests Lilly sees sufficient opportunity to extend its obesity leadership beyond its near-term commercialization pipeline.

While the report does not provide detailed clinical, regulatory, or timeline information about retatrutide, the thrust of the message is clear: Lilly wants investors and partners to focus not only on current Mounjaro and Zepbound demand, but also on the possibility that a broader set of weight-loss options could drive additional growth.

Industry context matters here because obesity drug markets are increasingly competitive and shaped by both efficacy data and manufacturing scale. When revenue beats come primarily from a single therapeutic area, companies often use earnings communications to confirm that they have follow-on assets that could sustain growth as demand, pricing, and competition evolve.

Still, several specifics are not disclosed in the post itself, including any trial phase commentary, regulatory status, or target milestones for retatrutide. Investors will likely need to look to future Lilly filings, investor presentations, or trial updates for the details that determine whether retatrutide can move from promise to another commercial pillar.